Floatz logo

METHOTREXATE

Moderate and Severe RheumatoId Arthritis

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Moderate and Severe RheumatoId Arthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Truway Health, Inc.
Phase 4BBB
IBUPROFEN
Amgen
Phase 3BB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BB
Tocilizumab
Hoffmann-La Roche
Phase 3BB
PREDNISONE TABLETS
Hoffmann-La Roche
Phase 3BB

View all 38 →

Same molecule, other indications

METHOTREXATE is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute promyelocytic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →